Alclofenac in ankylosing spondylitis

Eighteen patients with definite ankylosing spondylitis were treated with 3 to 4 g. alclofenac daily for up to 8 months in an open trial against previous therapy. Therapeutic efficacy was greater than or equivalent to previous therapy in 10 of 18 patients after 1 month and 8 patients remain on alclof...

Full description

Saved in:

Bibliographic Details
Published in:	Current medical research and opinion Vol. 3; no. 5; p. 321
Main Authors:	Bulgen, D Y, Hazleman, B L
Format:	Journal Article
Language:	English
Published:	England 1975
Subjects:	Adult Blood Sedimentation Clinical Trials as Topic Drug Eruptions - etiology Female Humans Indomethacin - therapeutic use Male Middle Aged Phenylacetates - adverse effects Phenylacetates - therapeutic use Phenylbutazone - therapeutic use Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - physiopathology Stomach Diseases - chemically induced
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Eighteen patients with definite ankylosing spondylitis were treated with 3 to 4 g. alclofenac daily for up to 8 months in an open trial against previous therapy. Therapeutic efficacy was greater than or equivalent to previous therapy in 10 of 18 patients after 1 month and 8 patients remain on alclofenac. There was a significant increase in symptoms, particularly morning stiffness after 1 month, but they tended to improve with time. Measurement of spinal movements was not found useful. Side-effects were commoner than expected but not serious. Alclofenac may prove a useful alternative drug in the management of ankylosing spondylitis and further trials are indicated.
ISSN:	0300-7995
DOI:	10.1185/03007997509114782